Tositumomab
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan=" | + | ! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] |
|- | |- | ||
! Parameter | ! Parameter | ||
Revision as of 06:38, 6 December 2010
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Clearance (L/h) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage (mg) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
